Sens.ai, the brain coach for life that uses neurotechnology and AI to improve cognitive healthspan, and Dr. Eric Verdin, President and CEO of the Buck Institute for Research on Aging, announce a collaboration to spearhead scientific advancement in brain health and longevity. Together, they’ll research and develop a biological clock designed to measure brain age, marking a potential shift in the understanding and treatment of age-related neurological decline.
The collaboration is founded on the hypothesis that the cutting-edge Sens.ai neurotechnology platform can both capture relevant biomarkers to quantify brain age and introduce brain training interventions to turn back the brain aging process. Both parties align on a shared mission to counter the effects of aging and extend human healthspan. The Buck Institute contributes a wealth of innovative research, state-of-the-art facilities, and decades of acclaimed expertise in the field of aging. Sens.ai provides the most advanced commercial neurotechnology platform with patent-pending hardware and software for high-integrity data capture for scalable discovery and insights.
Also Read: Danaher Appoints Martin Stumpe to New Role of Chief Data & Artificial Intelligence Officer
“We’re thrilled to join forces with the world-renowned Buck Institute and its all-star team of scientists led by Dr. Eric Verdin,” said Paola Telfer, Founder and CEO of Sens.ai. “This collaboration intersects our groundbreaking neurotechnology with The Buck Institute’s research in a synergistic way that can rapidly accelerate insights and developments to help extend healthspan for people everywhere.”
“Sens.ai’s technology is a breakthrough that can help us gather the right biomarkers with high integrity to conduct the analytics and research required to progress the longevity field in the area of the brain, which is the next frontier,” said Dr. Verdin, President and CEO of the Buck Institute.
By fusing the Sens.ai platform’s personalized light stimulation, neurofeedback, heart coherence training, and high-fidelity biosignal capture and brain function testing with the Buck Institute’s research expertise and scientific resources, the two companies are poised to catalyze scalable learnings that will benefit the longevity field faster, ultimately helping the most people possible.
SOURCE: PRNewswire
